Pyroptosis in epilepsy: from pathophysiological mechanisms to therapeutic strategies.

Overview

1. Department of Neurology, The Affiliated Hospital of Zunyi Medical University, Zunyi, Guizhou, China
2. Key Laboratory of Brain Function and Brain Disease Prevention and Treatment of Guizhou Province, Zunyi, China

Abstract

Epilepsy affects millions of individuals worldwide, however, approximately one-third of patients exhibit pharmacoresistance to currently available antiseizure therapies, underscoring an urgent unmet need for novel mechanism-based therapeutic strategies. Pyroptosis, a Gasdermin-mediated proinflammatory cell death, has recently been implicated as a pivotal driver of epileptogenesis and disease progression. This narrative critically evaluates emerging preclinical and clinical evidence linking pyroptotic signaling to epilepsy pathophysiology, with particular attention to cell-type-specific contributions. In astrocytes, GSDMD activation compromises blood–brain barrier (BBB) integrity, an effect mediated by the downregulation of endothelial tight junction proteins. In neurons, activation of the TRPM7/ROS/JAK2/STAT3 pathway drives pyroptosis, a process that also involves the interaction between NLRP3 and mitophagy. Microglial pyroptosis amplifies neuroinflammation, creating a self-perpetuating cycle. Clinically, the caspase-1 inhibitor VX-765 demonstrated favorable safety and preliminary efficacy in a Phase II randomized controlled trial in patients with refractory epilepsy; however, the trial did not meet its primary efficacy endpoint, suggesting that longer treatment durations may be required to assess its therapeutic potential. Preclinically, the GSDMD inhibitor disulfiram shows BBB-protective effects but is limited by off-target hepatotoxicity; conversely, development of the NLRP3 inhibitor MCC950 was discontinued following adverse hepatic findings in early clinical studies. Accumulating evidence also suggests that non-canonical pyroptotic pathways (caspase-4/5/11, GSDME) and PANoptosis, which integrates pyroptosis, apoptosis, and necroptosis, play a role in epileptic neuronal death. Major translational hurdles poor CNS bioavailability of candidate inhibitors, compensatory activation of parallel cell death pathways, and the absence of validated, clinically actionable biomarkers. Future efforts should therefore focus on developing cell-selective pyroptosis modulators, advanced CNS-targeted delivery platforms (e.g., nanoparticle- or antibody-conjugated systems), and biomarker-informed patient enrichment strategies to enable rational clinical translation of pyroptosis-directed therapeutics.

Reproduced under the paper's license (CC BY), from the paper cited above.

Code

The paper links to its data, not to its authors' code: see the Data section.

Tracing map

A tracing map links a paper to the code its authors published: this paper has none, so it has no map.

Data

Datasets cited

• geo:GSE99577, at NCBI GEO; found in the text, “Bioinformatics evidence”

Versions

The history of this record: each version stored by the harvester or made by a correction of its authors or of the maintainers of its code, and what changed in its facts. The texts of the paper (its abstract, its availability statements) are not part of it; versions that changed only those are not listed.

Version 1, 29 September 2026: the first record

Recorded: type, language, journal, volume, pages, dates, 5 authors, 6 keywords, 1 funder, 94 references.

Cite

This paper

Chen, Q., Yang, Y.-T., Cai, L., Zhang, H.-Q., & Yang, J. (2026). Pyroptosis in epilepsy: from pathophysiological mechanisms to therapeutic strategies. Frontiers in cell and developmental biology, 14, 1793636. https://doi.org/10.3389/fcell.2026.1793636

Similar papers

The papers with a page that share the most with this one: the tools found in their code, their categories, datasets, cited references and authors, the rarest counting most.

[1] doi:10.3390/toxics14050443 [code]

6PPDQ Exposure Exacerbates Seizure-Induced Neuronal Damage via the TP53/Nrf2 Axis: An Integrated Strategy Combining Network Toxicology and Experimental Validation.

Journal: Toxics

In common: epilepsy, cellular / molecular, 2 references

[2] doi:10.1038/s42003-026-10160-9 [code]

Low-intensity pulsed ultrasound promotes peripheral nerve regeneration by alleviating Schwann cells pyroptosis.

Journal: Communications biology

In common: cellular / molecular, 2 references

[3] doi:10.1155/humu/2963117

Construction of a Diagnostic Model and Drug Prediction for Postischemic Stroke Cognitive Impairment Based on Machine Learning Screening of Lactate Metabolism- and Pyroptosis-Related Genes.

Journal: Human mutation

In common: 2 references

[4] doi:10.1186/s12974-026-03837-9

PTP1B in astrocytes drives pathogen-induced neurodegeneration.

Journal: Journal of neuroinflammation

In common: cellular / molecular, 2 references

[5] doi:10.1016/j.isci.2026.116478

Deletion of Snap25 disrupts glial remodeling in aging mouse brain.

Journal: iScience

In common: cellular / molecular, 2 references

[6] doi:10.1016/j.bbi.2026.106824

Astrocyte reactivity by alcohol dependence in the central amygdala.

Journal: Brain, behavior, and immunity

In common: cellular / molecular, 2 references

[7] doi:10.3389/fnins.2026.1913179

Decoding astrocytic tryptophan metabolism in the pathogenesis of epilepsy: evidence from artificial intelligence-driven multi-omics and clinical validation.

Journal: Frontiers in neuroscience

In common: epilepsy, cellular / molecular, 1 reference

[8] doi:10.1038/s41593-026-02384-z [code]

cGAS-mediated type I IFN signaling contributes to disease progression in drug-refractory epilepsy.

Journal: Nature neuroscience

In common: epilepsy, cellular / molecular, 1 reference

[9] doi:10.3389/fnins.2026.1889410

Amino acid- and lipid-related metabolic remodeling in PTZ-kindled mice reveals candidate plasma signatures of chronic epilepsy.

Journal: Frontiers in neuroscience

In common: epilepsy, 1 reference

[10] doi:10.1186/s12974-026-03853-9 [code]

Mechanistically informed circulating biomarkers are associated with acquired epilepsy after neonatal brain injury.

Journal: Journal of neuroinflammation

In common: epilepsy, 1 reference

Contribute

The authors of this paper can claim it, correct its record and validate its tracing map, and the maintainers of its code (its owner, or a public member of its organization) correct what it says of their repository; anyone signed in can ask for its removal. Every request goes to OSCR's own machine, which answers it; your account page follows them.

Request its removal

To ask OSCR to remove this record, the copies of its authors' scripts or its tracing map, use the removal request page: signed in, you say who you are, what to remove and why, then review and confirm the request. Published rules decide every request (how).

Discussion: questions and error reports about this paper and its code, from signed-in readers and its authors. It opens with sign-in.

Reproductions: reports from readers who ran the authors' code: what they reproduced, with which environment, commit and data. It opens with sign-in.

Activity: what happens around this paper: new versions of its record, its map's validation, discussions and reproductions. It opens with sign-in.